Novo Nordisk's 9-months sales and operating profit up 6%

30 October 2020

Danish diabetes care giant Novo Nordisk (NOV: N) today posted financial results for the first nine months of 2020, showing that operating profits increased 6% (+7% at constant exchange rates) to 42.95 billion Danish kroner ($6.83 billion).

Net profit was up 9% at 32.82 kroner, and diluted earnings per share (EPS) were up 10% at 14.00 kroner. Novo Nordisk’s hares were down 1.3% at 41.33 kroner by midday.

Sales for the nine months rose 6% in kroner and by 7% at CER to 94.8 billion kroner. Sales in International Operations increased by 9% in kroner (12% at CER), and sales in North America Operations increased by 2% in kroner (+2% at CER). Sales growth was negatively impacted by COVID-19 as fewer patients initiated treatment, partially offset by COVID-19-related stocking in the first quarter, the company noted.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK